Brief: Rigel Announces First Patient Enrolled In Dose Expansion Phase Of 1B Study Of R289 In Patients With Lower-Risk MDS
08/10/2025 13:26
Oct 8 (Reuters) - Rigel Pharmaceuticals Inc RIGL.O: RIGEL ANNOUNCES FIRST PATIENT ENROLLED IN THE DOSE EXPANSION PHASE OF ITS PHASE 1B STUDY OF R289 IN PATIENTS WITH LOWER-RISK MDS Source text: ID:nPn7gYFvma Further company coverage: RIGL.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Rigel Pharmaceuticals
See all newsU.S. RESEARCH ROUNDUP- Berkshire Hathaway, Exxon Mobil, Honeywell Technologies
Rigel Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary
Rigel Pharmaceuticals Q2 revenue rises on strong product demand
Brief: Rigel Pharmaceuticals - Appoints Alison L. Hannah As Executive Vice President And Chief Medical Officer Effective July 1, 2026 - SEC Filing
Brief: Rigel Announces Closing Of Licensing Agreement For Veppanu (Vepdegestrant)